These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28247180)

  • 1. Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions.
    Lund LH; Oldgren J; James S
    Curr Heart Fail Rep; 2017 Apr; 14(2):59-70. PubMed ID: 28247180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design.
    Lund LH; James S; DeVore AD; Anstrom KJ; Fudim M; Aaronson KD; Dahlström U; Desvigne-Nickens P; Fleg JL; Yang S; Fu M; Hage C; Held C; Karlström P; Nygren M; Peterson ED; Pol T; Sapp S; Sundström J; Östlund O; Oldgren J; Pitt B
    Eur J Heart Fail; 2024 Nov; 26(11):2453-2463. PubMed ID: 39282788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registry-based randomised controlled trials: conduct, advantages and challenges-a systematic review.
    Shiely F; O Shea N; Murphy E; Eustace J
    Trials; 2024 Jun; 25(1):375. PubMed ID: 38863017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Registry-based randomized controlled trials merged the strength of randomized controlled trails and observational studies and give rise to more pragmatic trials.
    Mathes T; Buehn S; Prengel P; Pieper D
    J Clin Epidemiol; 2018 Jan; 93():120-127. PubMed ID: 28951111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Nothing to lose and the possibility of gaining": a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians.
    Prang KH; Karanatsios B; Zhang A; Verbunt E; Wong HL; Wong V; Gately L; Tran B; Gibbs P; Kelaher M
    Trials; 2023 Feb; 24(1):92. PubMed ID: 36747274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure registries - Future directions.
    Pol T; Karlström P; Lund LH
    J Cardiol; 2024 Feb; 83(2):84-90. PubMed ID: 37844799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining key design elements of registry-based randomised controlled trials: a scoping review.
    Karanatsios B; Prang KH; Verbunt E; Yeung JM; Kelaher M; Gibbs P
    Trials; 2020 Jun; 21(1):552. PubMed ID: 32571382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
    Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
    Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.
    Becher PM; Savarese G; Benson L; Dahlström U; Karlström P; Mol PGM; Metra M; Bhatt DL; Pitt B; Lund LH
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):343-352. PubMed ID: 36718512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
    Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
    Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry.
    O'Connor CM; Stough WG; Gallup DS; Hasselblad V; Gheorghiade M
    J Card Fail; 2005 Apr; 11(3):200-5. PubMed ID: 15812748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute heart failure: perspectives from a randomized trial and a simultaneous registry.
    Ezekowitz JA; Hu J; Delgado D; Hernandez AF; Kaul P; Leader R; Proulx G; Virani S; White M; Zieroth S; O'Connor C; Westerhout CM; Armstrong PW
    Circ Heart Fail; 2012 Nov; 5(6):735-41. PubMed ID: 23032196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paper I: Heterogeneous use of registry data for participant identification and primary outcome ascertainment is found in registry-based randomized controlled trials: A scoping review.
    Baba A; Tay J; Sammy A; Douglas WA; Goren K; Krause KR; Howie AH; Little J; Oskoui M; Taljaard M; Thombs BD; Potter BK; Butcher NJ; Offringa M
    J Clin Epidemiol; 2023 Jul; 159():289-299. PubMed ID: 37146658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Registry-based randomized clinical trials in surgery: Working with ACS-NSQIP and the AHPBA to conduct pragmatic trials.
    Ecker BL; Brajcich BC; Ellis RJ; Ko CY; D'Angelica MI
    J Surg Oncol; 2022 Jan; 125(1):89-92. PubMed ID: 34897710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paper II: thematic framework analysis of registry-based randomized controlled trials provided insights for designing trial ready registries.
    Krause KR; Tay J; Douglas WA; Sammy A; Baba A; Goren K; Thombs BD; Howie AH; Oskoui M; Frøbert O; Trakadis Y; Little J; Potter BK; Butcher NJ; Offringa M
    J Clin Epidemiol; 2023 Jul; 159():330-343. PubMed ID: 37146660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial.
    Marquis-Gravel G; Robertson H; Jones WS; Riley D; Ford DE; Crenshaw D; Joosten YA; Rudov L; Hernandez AF; Hess R
    Trials; 2021 Jan; 22(1):90. PubMed ID: 33494785
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.